Scarica l'app Stockscreener
0.9628
4.67%
-0.0472
Pre-mercato:
.96
-0.0028
-0.29%
Precedente Chiudi:
$1.01
Aprire:
$1.02
Volume 24 ore:
530.11K
Relative Volume:
0.69
Capitalizzazione di mercato:
$54.64M
Reddito:
$21.05M
Utile/perdita netta:
$-89.22M
Rapporto P/E:
-0.5379
EPS:
-1.79
Flusso di cassa netto:
$-64.50M
1 W Prestazione:
-3.72%
1M Prestazione:
-12.47%
6M Prestazione:
-37.88%
1 anno Prestazione:
-66.22%
Intervallo 1D:
$0.9614
$1.05
Intervallo di 1 settimana:
$0.9614
$1.09
Portata 52W:
$0.91
$3.43
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Nome
Tscan Therapeutics Inc
Settore
Industria
Telefono
857-399-9500
Indirizzo
830 WINTER STREET, WALTHAM
Confronta TCRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
0.9628 | 57.32M | 21.05M | -89.22M | -64.50M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-05-16 | Iniziato | BTIG Research | Buy |
| 2024-05-13 | Iniziato | Needham | Buy |
| 2023-06-22 | Iniziato | Wedbush | Outperform |
Tscan Therapeutics Inc Borsa (TCRX) Ultime notizie
Tscan Therapeutics stock holds Neutral rating at BTIG after ASH event - Investing.com Canada
TScan Therapeutics announces updated data from ALLOHA Phase 1 trial - MSN
TScan Therapeutics : ASH 2025 Virtual KOL Presentation - marketscreener.com
Wall Street analysts’ outlook for Tscan Therapeutics Inc (TCRX) - setenews.com
TCRX: TSC-101 shows durable efficacy and safety, with pivotal trial and market expansion set for next year - TradingView
Investor MeetingKey Opinion Leader - marketscreener.com
TScan Therapeutics Announces Positive Updated Data from the - GlobeNewswire
How Low Can TScan Therapeutics Stock Really Go? - Trefis
TScan Therapeutics (TCRX) Price Target Increased by 10.53% to 7.14 - Nasdaq
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Rating of "Hold" from Analysts - MarketBeat
Is TScan Therapeutics Stock Built to Withstand a Pullback? - Trefis
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points - The Malaysian Reserve
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points (2025-12-04) - Seeking Alpha
TScan to host KOL event discussing updated ALLOHA trial data By Investing.com - Investing.com Canada
TScan Therapeutics To Provide Update On Phase 1 Trial Of TSC-101 In Heme Malignancies Next Week - Nasdaq
TScan to host KOL event discussing updated ALLOHA trial data - Investing.com India
TScan Therapeutics to Host Virtual KOL Event on ALLOHA™ Phase 1 Trial Data and Market Opportunities - Quiver Quantitative
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities - The Manila Times
TScan Therapeutics, Inc. (TCRX) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
How TScan Therapeutics Inc. stock reacts to oil pricesJuly 2025 Reactions & Community Driven Trade Alerts - moha.gov.vn
Is TScan Therapeutics Inc a good long term investmentStock Liquidity Analysis & Free Tools to Find Winning Stocks - earlytimes.in
Is TScan Therapeutics Inc. stock dividend yield sustainableTrade Exit Report & Daily Technical Stock Forecast Reports - BỘ NỘI VỤ
TScan Therapeutics Approves Key Employee Retention Program - TipRanks
TScan Therapeutics ties executive pay to pivotal TSC-101 trial - Stock Titan
American Society of Hematology Meeting - marketscreener.com
Cluey Ltd Launches $4.5 Million Entitlement Offer - The Globe and Mail
Tscan Therapeutics Inc (TCRX) is looking forward to a strong quarter - Setenews
Reversal indicators forming on TScan Therapeutics Inc. stockProfit Target & Consistent Profit Alerts - newser.com
Is TScan Therapeutics Inc. stock positioned well for digital economyTrade Ideas & Daily Oversold Bounce Ideas - newser.com
Applying chart zones and confluence areas to TScan Therapeutics Inc.2025 Pullback Review & Reliable Price Breakout Alerts - newser.com
Is TScan Therapeutics Inc. building a consolidation baseJuly 2025 Closing Moves & Safe Capital Growth Stock Tips - newser.com
How TScan Therapeutics Inc. stock performs in high volatility markets2025 Market Outlook & Expert Curated Trade Setups - newser.com
TScan Therapeutics (NASDAQ:TCRX) Cut to Equal Weight at Morgan Stanley - Defense World
Equities Analysts Issue Forecasts for TCRX FY2025 Earnings - Defense World
Best data tools to analyze TScan Therapeutics Inc. stockJuly 2025 Macro Moves & Daily Growth Stock Tips - newser.com
How TScan Therapeutics Inc. stock reacts to global recession fears2025 Major Catalysts & Growth Oriented Trading Recommendations - newser.com
HC Wainwright Cuts TScan Therapeutics (NASDAQ:TCRX) Price Target to $7.00 - Defense World
Should you wait for a breakout in TScan Therapeutics Inc.Weekly Risk Summary & Scalable Portfolio Growth Methods - newser.com
How TScan Therapeutics Inc. stock performs in rate cut cyclesWeekly Trade Review & Real-Time Stock Movement Alerts - newser.com
Using data filters to optimize entry into TScan Therapeutics Inc.2025 Earnings Impact & Technical Pattern Recognition Alerts - newser.com
Morgan Stanley Downgrades TScan Therapeutics to Equalweight From Overweight - MarketScreener
Tscan Therapeutics Inc Azioni (TCRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):